Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

NCT02914691 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Diabetic Nephropathy

Interventions

DRUG: Dapagliflozine 10 mg once daily tablet treatment
DRUG: Placebo identical once daily tablet treatment

Sponsor

Peter Rossing